Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin…
Good lesson. Our risk control tactics help us make money and lessen risk. We NEVER argue with price. We keep losses SMALL. Those were GREAT SELLS on $KNSA . Look at it now. Great to be OUT from up much higher. #missionwinners #investing https://t.co/muYe7QF56D
Stock Market Today with @AlissaCoram and @IBD_ECarson Major indexes test resistance; Lindblad, Kiniksa Pharmaceuticals, Guidewire in focus $LIND $KNSA $GWRE https://t.co/tKEiuRo3vn
8 analysts rate KNSA Buy on consensus.
Consensus price target: $57.38 (-28.47% downside from $80.22)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Megna Michael R CHIEF ACCOUNTING OFFICER | Sep 3, 2026 | Sale | 4,600 | $369.38K |
| Cole G Bradley director | Jul 29, 2026 | Sale | 3,673 | $299.09K |
| Patel Sanj K director, CHAIRMAN & CEO | May 1, 2026 | Sale | 48,565 | $2.62M |
| Patel Sanj K director, CHAIRMAN & CEO | Apr 30, 2026 | Sale | 2,141 | $115.64K |
| Patel Sanj K director, CHAIRMAN & CEO | Apr 28, 2026 | Sale | 51,750 | $2.8M |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $677.56M | +60.09% | $59.01M |
| 2024 | $423.24M | +56.6% | $-43.19M |
| 2023 | $270.26M | +22.74% | $14.08M |
Stock data for KNSA: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics